Citryll Administers Initial Dose in Phase IIa Trial of Monoclonal Antibody for Rheumatoid Arthritis

Trial Initiation: Citryll has commenced a Phase IIa trial, Citydream, for its monoclonal antibody CIT-013, targeting individuals with moderately active rheumatoid arthritis (RA), with the first subject dosed in a multi-centre, double-blind, placebo-controlled study across Europe.

Study Objectives and Future Plans: The trial aims to assess the safety, tolerability, and efficacy of CIT-013 over six weeks, with plans for an open-label extension. Citryll is also preparing for another Phase IIa study for hidradenitis suppurativa later this year.